Topics
January 2009 | Diabetic Retinopathy Feature
The Economic Burden of Diabetic Macular Edema
Cost-effectiveness of therapy is a complex equation.
George A. Williams, MD
June 24, 2026
Kalaris to Present Phase 1a Data on VEGF/HSPG Biologic at ASRS 2026
Ollin Biosciences Raises $330 Million to Advance Phase 3 Development of VEGF/Ang2 bispecific Antibody
June 23, 2026
Oculgen Announces First US Patient Enrolled in STAT Trial of OCUL101 for Wet AMD
June 22, 2026
Atsena Doses First Patient in Phase 3 LIGHTHOUSE Trial of Gene Therapy for XLRS
May/June 2026 Insert
Editorially Independent Content, Supported With Advertising From Astellas
Supported by Zeiss
Editorially independent supported by Abbvie and Regenxbio
May/June 2026 Supplement
Free Print Subscription
Email Newsletter
Conference Calendar
